Presentation: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)

Robert J. Hopkin, Cincinnati Children’s Hospital Medical Center

• Platform Presentation: Wednesday, February 7, 2024 – 8:00am PT
• Poster Session: Wednesday, February 7, 2024 – 3-5pm PT (Poster: 145)